Clinical Trial Update: Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing zoledronic acid to alendronate for prevention of bone loss after organ transplantation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption
• Heart Transplantation
• Liver Transplantation

Drugs mentioned

• Zoledronic acid (Zoledronic acid)
• alendronate (alendronate)

Snippet

Sponsor: Columbia University | Conditions: Heart Transplantation, Liver Transplantation | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2016-09-15